[{"id":"7a975757-8211-4b36-ac38-b3c22e81b775","acronym":"Cornerstone4","url":"https://clinicaltrials.gov/study/NCT05794659","created_at":"2023-04-03T14:02:47.465Z","updated_at":"2024-07-02T16:35:42.411Z","phase":"Phase 2","brief_title":"Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer","source_id_and_acronym":"NCT05794659 - Cornerstone4","lead_sponsor":"Aston Sci. Inc.","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • EP-201 • Leukine (sargramostim)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 11/15/2023","start_date":" 11/15/2023","primary_txt":" Primary completion: 11/15/2025","primary_completion_date":" 11/15/2025","study_txt":" Completion: 11/15/2027","study_completion_date":" 11/15/2027","last_update_posted":"2023-07-20"},{"id":"a5694c4f-4a89-466f-8e70-101ab026d285","acronym":"","url":"https://clinicaltrials.gov/study/NCT01322802","created_at":"2021-01-18T05:23:07.202Z","updated_at":"2024-07-02T16:36:34.081Z","phase":"Phase 1","brief_title":"Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer","source_id_and_acronym":"NCT01322802","lead_sponsor":"University of Washington","biomarkers":" IFNG • IGFBP2","pipe":"","alterations":" ","tags":["IFNG • IGFBP2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EP-201"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 03/06/2012","start_date":" 03/06/2012","primary_txt":" Primary completion: 01/09/2015","primary_completion_date":" 01/09/2015","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2021-02-25"}]